Cargando…

Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

BACKGROUND: Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer. With the introduction of new treatment classes, it is important to examine patient symptom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davie, Alison, Carter, Gebra Cuyun, Rider, Alex, Pike, James, Lewis, Katie, Bailey, Abigail, Price, Gregory L., Ringeisen, Francois, Pivot, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487722/ https://www.ncbi.nlm.nih.gov/pubmed/32894087 http://dx.doi.org/10.1186/s12885-020-07294-2

Ejemplares similares

Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study
por: Davie, A., et al.
Publicado: (2021)

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Advanced Breast Cancer: A Systematic Literature Review
por: Cuyún Carter, Gebra, et al.
Publicado: (2021)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy
por: Davie, Alison, et al.
Publicado: (2023)

Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States
por: Aggarwal, Himani, et al.
Publicado: (2020)

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
por: Cuyún Carter, Gebra B, et al.
Publicado: (2011)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
por: Porte, B., et al.
Publicado: (2020)

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
por: Salvo, Elizabeth M., et al.
Publicado: (2021)

Effect of HER2 expression status on the prognosis of patients with HR(+)/HER2(‑) advanced breast cancer undergoing advanced first‑line endocrine therapy
por: Wang, Kan, et al.
Publicado: (2023)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
por: Wei, Qiran, et al.
Publicado: (2023)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer
por: Cuyún Carter, Gebra, et al.
Publicado: (2014)

Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol
por: Hess, Lisa M, et al.
Publicado: (2017)

Data Integration to Improve Real-world Health Outcomes Research for Non–Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration
por: Grabner, Michael, et al.
Publicado: (2021)

Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study
por: Shen, Xia-Bo, et al.
Publicado: (2021)

Efficacy and safety of palbociclib plus endocrine therapy for patients with HR(+)/HER2(−) advanced breast cancer in real-world clinical practice
por: Zhong, Bingqian, et al.
Publicado: (2022)

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
por: Toi, Masakazu, et al.
Publicado: (2021)

KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis
por: Carter, Gebra Cuyun, et al.
Publicado: (2015)

The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives
por: Bly, Christopher A., et al.
Publicado: (2018)

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(−) advanced breast cancer: results from BOLERO-2
por: Moynahan, Mary Ellen, et al.
Publicado: (2017)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

Automated Quantification of Extranuclear ERα Using Phosphor-Integrated Dots for Predicting Endocrine Therapy Resistance in HR(+)/HER2(−) Breast Cancer
por: Guo, Zhaorong, et al.
Publicado: (2019)

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
por: Zhang, Qing Yuan, et al.
Publicado: (2020)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Publicado: (2023)

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
por: Mycock, Katie, et al.
Publicado: (2021)

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
por: Jeong, Eunae, et al.
Publicado: (2021)

CERN HR receives award for on-line recruitment and communication
por: Joannah Caborn Wengler
Publicado: (2012)

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR(+)/HER2(−) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
por: Lu, Yen-Shen, et al.
Publicado: (2022)

Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis
por: Vickers, Adrian D., et al.
Publicado: (2019)

Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer
por: Gibbs, Sarah N., et al.
Publicado: (2023)

Survival in patients with HR+/HER2− metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study
por: Simon, Julien, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8rfuhp2c3l0trqg4tipm6gpmql